Knight Therapeutics (TSE:GUD)
TSX:GUD
GUD Stock Chart & Stats
C$7.69
-C$0.03(-0.46%)
At close: 4:00 PM EST
C$7.69
-C$0.03(-0.46%)
Day’s Range― - ―
52-Week RangeC$5.43 - C$7.74
Previous CloseN/A
Volume40.10K
Average Volume (3M)48.52K
Market Cap
C$753.89M
Enterprise ValueC$765.00M
Total Cash (Recent Filing)C$95.28M
Total Debt (Recent Filing)C$77.91M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
May 07, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding98,034,744
10 Day Avg. Volume49,308
30 Day Avg. Volume48,518
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$8.96Price Target Upside16.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)C$484.73M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a sizable equity base provide structural financial flexibility. This strengthens the company’s ability to weather regulatory or product setbacks, fund in-licensing and launches, and pursue M&A or working-capital needs without immediate external financing, supporting durable operations.
Improving Cash GenerationSustained improvement in operating and free cash flow enhances internal funding for commercialization and product rollouts, reduces reliance on debt, and improves resilience to cyclical revenue swings. Strong cash generation underpins long-term reinvestment and strategic optionality.
Record Revenues, Raised Guidance, Portfolio ExpansionRecord top-line and EBITDA alongside higher guidance indicate durable revenue momentum from recent deals. The strategic in‑licensing and oncology expansion broaden the product mix and reduce single-product concentration, supporting more predictable future growth and therapeutic diversification.
Bears Say
Inconsistent ProfitabilityRepeated swings in net income reveal fragile operating leverage and limited durability of margins. This undermines forecastability of earnings, complicates long-term planning for reinvestment or dividends, and increases sensitivity to product performance or one-off items.
Regulatory SetbacksRegulatory rejections and prolonged appeals (Brazil appeal may take up to 14 months) materially delay market access, revenue realization, and ROI on in‑licensed products. Persistent regulatory risk can slow portfolio commercialization and strain marketing investments over many quarters.
Investment Volatility ImpactExposure to marked‑to‑market strategic investments introduces earnings volatility unrelated to core operations. Capital losses or valuation swings can erode equity, complicate cash planning, and distract management from commercialization priorities, reducing predictability of long‑term returns.
Knight Therapeutics News
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$5.43 and its highest was C$7.74 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is C$753.89M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 29 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Mar 19, 2026. The company reported C$0.09 earnings per share for the quarter, beating the consensus estimate of -C$0.004 by C$0.094.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is 0.03.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 98,034,744 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of C$0.09 in its last earnings report, beating expectations of -C$0.004. Following the earnings report the stock price went up 2.107%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
GUD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.View all TSE:GUD earnings summariesGUD Stock 12 Month Forecast
Average Price Target
C$8.96
▲(16.53% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Organigram Global
―
Aurora Cannabis
―
Cronos Group
―
HLS Therapeutics Inc
―
Options Prices
Currently, No data available
---